Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,092 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The transcription factor ZEB2 drives the formation of age-associated B cells.
Dai D, Gu S, Han X, Ding H, Jiang Y, Zhang X, Yao C, Hong S, Zhang J, Shen Y, Hou G, Qu B, Zhou H, Qin Y, He Y, Ma J, Yin Z, Ye Z, Qian J, Jiang Q, Wu L, Guo Q, Chen S, Huang C, Kottyan LC, Weirauch MT, Vinuesa CG, Shen N. Dai D, et al. Among authors: hong s. Science. 2024 Jan 26;383(6681):413-421. doi: 10.1126/science.adf8531. Epub 2024 Jan 25. Science. 2024. PMID: 38271512 Free PMC article.
The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.
Guruprasad P, Carturan A, Zhang Y, Cho JH, Kumashie KG, Patel RP, Kim KH, Lee JS, Lee Y, Kim JH, Chung J, Joshi A, Cohen I, Shestov M, Ghilardi G, Harris J, Pajarillo R, Angelos M, Lee YG, Liu S, Rodriguez J, Wang M, Ballard HJ, Gupta A, Ugwuanyi OH, Hong SJA, Bochi-Layec AC, Sauter CT, Chen L, Paruzzo L, Kammerman S, Shestova O, Liu D, Vella LA, Schuster SJ, Svoboda J, Porazzi P, Ruella M. Guruprasad P, et al. Among authors: hong sja. Nat Immunol. 2024 Jun;25(6):1020-1032. doi: 10.1038/s41590-024-01847-4. Epub 2024 Jun 3. Nat Immunol. 2024. PMID: 38831106
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, He ZY, Chen NY, Hu WH, Wu HJ, Shi M, Zhou GQ, Mao YP, Guo R, Sun R, Huang J, Liang SQ, Wu WL, Su Z, Li L, Ai P, He YX, Zang J, Chen L, Lin L, Huang SH, Xu C, Lv JW, Li YQ, Hong SB, Jie YS, Li H, Huang SW, Liang YL, Wang YQ, Peng YL, Zhu JH, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Lin AH, Li JB, Liu N, Tang LL, Chen YP, Sun Y, Ma J. Liu X, et al. Among authors: hong sb. Lancet. 2024 May 30:S0140-6736(24)00594-4. doi: 10.1016/S0140-6736(24)00594-4. Online ahead of print. Lancet. 2024. PMID: 38824941
21,092 results
You have reached the last available page of results. Please see the User Guide for more information.